Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 401 - 450 out of 10,564

Document Document Title
WO/2010/078449A2
The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-sta...  
WO/2010/072831A1
An oligonucleotide which comprises at least one internucleotide linkage comprising a P-S-R bond and at least two nucleosides, wherein R corresponds to the formula (I) wherein A is a geminally substituted alkylene group, preferably CH2, X...  
WO/2010/072734A2
Provided herein are compounds, compositions and methods for preventing or treating gastrointestinal cancer in a mammal, wherein the method comprises delivering an effective amount of a COX-2 or a similar sulfonamide inhibitor as a prodru...  
WO/2010/074062A1
Aminoethanol is reacted with a fluoroalkylsulfonic anhydride to obtain a fluoroalkylsulfonylaminoethanol (first step: sulfonylamidation step). The fluoroalkylsulfonylaminoethanol is esterified with an α-substituted acrylate derivative t...  
WO/2010/072734A3
Provided herein are compounds of formula (I) as well as compounds of formula (I) which are prodrugs in which the (R7)a-phenyl-S(O)2NH group represents a sulphonamide-bond compound, compositions and methods for preventing or treating gast...  
WO/2010/070615A1
Compounds of the formula I wherein R1a is H; and R1b is C1-C6 alkyl, Carbocyclyl or Het; or R1a and R1b together define a saturated cyclic amine with 3-6 ring atoms; R2a and R2b are H, halo, C1-C4alkyl, C1-C4haloalkyl, C1-C4alkoxy; or R2...  
WO/2010/070076A1
The invention related to alkanoic acid derivatives of Formula (IIa) and (IIb). These compounds of the invention were found to have activity as HDAC inhibitors.  
WO/2010/066847A1
The present invention concerns novel substituted aryl derivatives, their process of preparation and their use for inhibiting virus replication and for treating viral diseases or disorders such as HIV and/or HCV infection.  
WO/2010/057865A1
A compound of formula (I) and salts thereof are provided: Wherein n and R1 are defined in the specification. Processes for preparation, pharmaceutical compositions, and uses thereof as a medicament, for example in the treatment of a dise...  
WO/2010/056527A2
The present invention relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the co...  
WO/2010/055005A1
The invention is concerned with the compounds of formula (I) and pharmaceutically acceptable salts and esters thereof, wherein X, Q, and R1-R6 are defined in the detailed description and claims. In addition, the present invention relates...  
WO/2010/056527A3
The present invention relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the co...  
WO/2010/055887A1
A novel β-(trifluoromethyl)vinyldiaryl sulfonium salt represented by general formula (I), which can be used for simple syntheses of various useful compounds each containing a trifluoromethyl group, or the like. (In formula (I), R1 and R...  
WO/2010/051933A3
The present invention relates to substituted sulphonamido phenoxybenzamide compounds of general formula (I) in which A, R1, R2, R3, R4, R5, R6, R7, R8 and n are as defined in the claims, to pharmaceutical compositions and combinations co...  
WO/2010/051933A2
The present invention relates to substituted sulphonamido phenoxybenzamide compounds of general formula (I) in which A, R1, R2, R3, R4, R5, R6, R7, R8 and n are as defined in the claims, to pharmaceutical compositions and combinations co...  
WO/2010/049946A2
The present invention relates to novel compounds of general formula (I) which are thyroid receptor ligands and are preferably selective for the thyroid hormone receptor beta (TR-Beta). Further, the present invention relates to processes ...  
WO/2010/049946A3
The present invention relates to novel compounds of general formula (I) which are thyroid receptor ligands and are preferably selective for the thyroid hormone receptor beta (TR-Beta). Further, the present invention relates to processes ...  
WO/2010/048332A2
Provided are compounds, pharmaceutical compositions thereof, and methods of treating ophthalmic diseases and disorders, such as age-related macular degeneration and Stargardt's Disease, using said compounds and compositions.  
WO/2010/048332A3
Provided are compounds, pharmaceutical compositions thereof, and methods of treating ophthalmic diseases and disorders, such as age-related macular degeneration and Stargardt's Disease, using said compounds and compositions.  
WO/2010/044686A1
The invention is based on the finding that the enzyme AKR1C3 is capable of exhibiting nitroreductase activity and activating nitroaromatic prodrugs to release the cytotoxic effector. AKR1C3-activated nitroaromatic prodrugs include dinitr...  
WO/2010/043000A1
The invention relates to novel compounds that have S1P receptor modulating activity. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions cau...  
WO/2010/044685A1
The invention provides nitrophenyl mustard compounds useful in cancer therapy as targeted cytotoxic agents, of Formula (I) and Formula (II): wherein X represents C1, Br, I, or OSO2R1, Y represents C1, Br, I, or OSO2R1, Z represents at an...  
WO/2010/041748A1
Disclosed is a prophylactic or therapeutic agent for diabetes, diabetic complications, insulin resistance syndrome, metabolic syndrome, hyperglycemia, dyslipidemia, atherosclerosis, heart failure, cardiomyopathy, myocardial ischemia, cer...  
WO/2010/032010A1
The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-phenyl-sulfonamido-phenylene compounds of the following formula (I) (collectively referred to herein as "APSAP compound...  
WO/2010/032009A1
The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-phenyl-sulfonamido-cycloalkyl compounds of the following formula (collectively referred to herein as "APSAC compounds")...  
WO/2010/030781A2
Prodrug compounds which metabolize into 5-ASA or analogs thereof, and taurine or analogs thereof, in the colon site are disclosed. Pharmaceutical compositions including the compounds, and methods of treatment using the compounds, are als...  
WO/2010/028968A3
The application discloses novel polymorphic crystalline forms of 2-[4-Bromo-3-(3-chloro- 5-cyano-phenoxy)-2-fluoro-phenyl]-N-(2-chloro-4-propionylsul famoyl-phenyl)-acetamide, sodium salt (Ib) with improved stability and physical propert...  
WO/2010/028968A2
The application discloses novel polymorphic crystalline forms of 2-[4-Bromo-3-(3-chloro- 5-cyano-phenoxy)-2-fluoro-phenyl]-N-(2-chloro-4-propionylsul famoyl-phenyl)-acetamide, sodium salt (Ib) with improved stability and physical propert...  
WO/2010/030781A3
Prodrug compounds which metabolize into 5-ASA or analogs thereof, and taurine or analogs thereof, in the colon site are disclosed. Pharmaceutical compositions including the compounds, and methods of treatment using the compounds, are als...  
WO/2010/028088A3
Provided are sulphur-linked compounds, pharmaceutical compositions thereof, and methods of treating ophthalmic diseases and disorders, such as age-related macular degeneration and Stargardt's Disease, using said compounds and compositions.  
WO/2010/028088A2
Provided are sulphur-linked compounds, pharmaceutical compositions thereof, and methods of treating ophthalmic diseases and disorders, such as age-related macular degeneration and Stargardt's Disease, using said compounds and compositions.  
WO/2010/023448A1
The present invention provides a compound of formula (I) or its salts or pharmaceutically acceptable derivatives thereof wherein; X1 is selected from a group consisting of CH2, C(=O), C(=NH), NC(=O), R1 is selected from the group consist...  
WO/2010/023446A1
The present invention provides a compound of formula (I) or its salts or pharmaceutically acceptable derivatives thereof wherein; X1 is selected from a group consisting of CH, O or N; R1 is selected from the group consisting of optionall...  
WO/2010/020719A1
The present invention relates to the compound of formula (I) and to the use thereof as an intermediate for the synthesis of the compound of formula (A) or pharmaceutically acceptable salts thereof: formulae (II).  
WO/2010/018113A3
The invention is concerned with the compounds of formula (I) and pharmaceutically acceptable salts and esters thereof, wherein R1-R5, A, B, Q, W, and X are defined in the detailed description and claims. In addition, the present inventio...  
WO/2010/018112A3
The invention is concerned with the compounds of formula (I): and pharmaceutically acceptable salts and esters thereof, wherein R1, R2 and R3 are defined in the detailed description and claims. In addition, the present invention relates ...  
WO/2010/018112A2
The invention is concerned with the compounds of formula (I): and pharmaceutically acceptable salts and esters thereof, wherein R1, R2 and R3 are defined in the detailed description and claims. In addition, the present invention relates ...  
WO/2010/018113A2
The invention is concerned with the compounds of formula (I) and pharmaceutically acceptable salts and esters thereof, wherein R1-R5, A, B, Q, W, and X are defined in the detailed description and claims. In addition, the present inventio...  
WO/2010/018109A2
The invention is concerned with the compounds of formula (I), and pharmaceutically acceptable salts and esters thereof, wherein R1-R4 are defined in the detailed description and claims. In addition, the present invention relates to metho...  
WO/2010/018109A3
The invention is concerned with the compounds of formula (I), and pharmaceutically acceptable salts and esters thereof, wherein R1-R4 are defined in the detailed description and claims. In addition, the present invention relates to metho...  
WO/2010/015655A1
There are described cyclohexyl amide derivatives useful as corticotropin releasing factor (CRF1) receptor antagonists.  
WO/2010/017470A1
The present invention is directed to a compound represented by Structural Formula (A): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (A) are defined herein. Also described is a pharmaceutical composi...  
WO/2010/015613A1
The present invention relates to compounds of Formula (I) wherein X, R1, R2, R3, R4 and R5 are as defined herein, which are useful for treating diseases which respond to CXCR2 receptor mediators. Pharmaceutical compositions that contain ...  
WO/2010/013567A1
Disclosed is a pest control agent having an excellent effect, which contains, as an active ingredient, a compound represented by general formula (1). (In the formula, A represents a carbon atom, a nitrogen atom or the like; K represents...  
WO/2010/009508A1
A compound of Formula (A) wherein Z is an aryl, substituted aryl, heteroaryl, or substituted heteroaryl, wherein the heteroaryl or substituted heteroaryl connected to a 2,4-dinito-6-(trifluoromethyl)phenyl ring via a carbon-carbon bond.  
WO/2010/010079A1
The invention relates to aryl-sulphonamido compounds endowed with affinity against metallo proteases MMP, having formula (I) below wherein R, R1, R2, R3, G and n have the meanings reported in the specification, properly labelled with dia...  
WO/2010/010080A1
The invention relates to dimeric aryl-sulphonamido compounds endowed with inhibitory activity against metalloproteases MMP, having formula (I) below (M)-L-(M') (I), wherein M and M', the same or different from each other, represent the r...  
WO/2010/007027A1
The present invention provides a compound of formula (I) said compound is inhibitor of MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-12 and/or MMP- 13....  
WO/2010/009068A2
The present application describes modulators of MCP-1 or CCR-2 of formula,(I) or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein T, W, X, Y, Z, R1, R2, R4 and R6, are defined herein. In addition, methods o...  
WO/2010/009068A3
The present application describes modulators of MCP-1 or CCR-2 of formula,(I) or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein T, W, X, Y, Z, R1, R2, R4 and R6, are defined herein. In addition, methods o...  

Matches 401 - 450 out of 10,564